Introduction
Insulin replacement is essential for maintaining the health of patients with type I diabetes mellitus. Many patients with type II diabetes also require insulin to control their blood glucose levels. Recent progress in molecular biology has fostered the development of gene therapy as a new therapeutic strategy. [1] [2] [3] Diabetes mellitus has long been considered to be curable with insulin gene therapy. 4, 5 However, several unsolved problems currently hamper the use of insulin gene therapy in clinical practice. First, to regulate blood glucose levels without risking the development of hypoglycemia, any insulin secretion derived from the vector construct must be regulated by changes in blood glucose levels. Second, the gene expression vector used must be capable of prolonged expression. Third, an efficient and minimally invasive vector delivery system is required.
With regard to the first of these issues, recent studies have reported that insulin secretion from genes delivered to the liver can be controlled at the transcriptional level by blood glucose levels. [6] [7] [8] However, the drawback of this system is that the slow transcriptional regulation of this hepatic insulin gene expression delays the responsiveness of the plasma insulin levels to blood glucose changes. 6 Notably, Liu et al. 9 recently demonstrated that cotransfection a hepatoma cell line with the insulin and GLUT 2 transporter genes induces ATP-sensitive potassium (K ATP ) channels and leads to glucose-stimulated insulin secretion. Thus, cotransfection with the GLUT 2 gene may result in more timely glucose-regulated secretion of the insulin encoded by the insulin transgene.
With regard to the second of the issues hampering gene therapy, prolonged gene expression has been achieved by employing an Epstein-Barr virus (EBV)-based plasmid. The application of this plasmid in various cells has been developed. [10] [11] [12] EBV is of particular interest as a vector because of its latent infection property, which is characterized by autonomous replication and nuclear retention of the EBV genome in host cells. 13 The persistent maintenance of the EBV genome has been analyzed in depth and is mediated by the replication origin of the latent viral DNA (oriP) and EBV nuclear antigen 1 (EBNA-1). 14, 15 Previously, our group showed that use of the EBV replicon vector leads to sustained transgene expression in vivo in the liver. 11 With regard to efficient vector delivery, numerous viral and nonviral vectors have been developed. 4 Adenovirus-mediated gene transfer has been successful in transiently expressing transgenes, but it also causes undesired effects such as hepatic inflammation. 16, 17 Adeno-associated virus (AAV) is an attractive choice for insulin gene therapy. A recent study showed the safety and efficacy of AAV-mediated insulin gene transfer into streptozotocin (STZ)-induced diabetic rats. 18 Although AAVs generally have low immunogenicity, 19 a potential caveat of this approach is the possible generation of neutralizing antibody that might limit readministration. In addition, a large proportion of the human population has pre-existing antibodies against AAV that may limit gene transfer by this virus. 4, 20 Nonviral vectors are less toxic and less immunogenic, 21 but most are also less efficient, especially in vivo. Gene therapy strategies employing the hemagglutinating virus of Japan (HVJ)-liposome system have recently met with success in animals. [22] [23] [24] [25] Also, Kaneda et al. recently developed the HVJ-envelope (HVJ-E) vector system, which is a simple method to convert an inactivated virus containing lipid envelop into gene transfer vector. They used this technology to introduce plasmid DNA directly into inactivated HVJ-E and investigated the feasibility of using this HVJ-E vector for gene transfer.
HVJ-E vector is even more effective than HVJ-liposomes for in vivo gene transfer. 26 Finally, gene transfer to the liver, lung, uterus, eye, skin, muscle and brain of animals such as rat, mouse, rabbit and monkey has been achieved by the direct injection of the HVJ-E vector. Among the various organs tested, HVJ-E vector was more effective than HVJ-liposome for gene transfer to the liver, uterus, brain and lung.
Here, we show the efficacy of cotransfecting hepatic cells with an EBV replicon vector encoding human insulin and GLUT 2 transporter (referred to here as pEBAct-ins and pEBAct-glut2, respectively) by using the HVJ-E vector. Significantly, this novel gene therapy was highly effective in treating hyperglycemia in STZinduced diabetic rats. Moreover, cotransfected diabetic rats were able to regulate their glucose levels in response to exogenous glucose levels in a physiologically appropriate manner.
Results

Hepatic insulin and GLUT 2 gene expression
We examined the effectiveness of in vivo gene transfer by immunohistochemical analysis of insulin and GLUT 2 proteins. We directly injected the HVJ-E vector bearing pEBAct-ins with or without pEBAct-glut2 into the STZinduced diabetic rat liver. At 4 days after the transfection of pEBAct-ins with or without pEBAct-glut2, the rat liver showed expression of insulin (Figure 1b and c) . In contrast, in the control vector-transfected rat, positive Anti-insulin antibody (a-d) or anti-GLUT2 antibody (e-g) staining of liver sections from STZ-induced diabetic rats treated with control vector (a, e), pEBAct-ins (b, f), or pEBAct-ins plus pEBActglut2 (c, g) and killed 4 days later. (d) Anti-insulin antibody staining of liver sections from a STZ-induced diabetic rat treated with pEBAct-ins plus pEBAct-glut2 and killed 25 days later. (h) Western blot analysis of hepatic GLUT 2 expression in diabetic control transfected with control vector and in STZ-induced diabetic rats treated with pEBAct-ins with or without pEBAct-glut2. Total protein was extracted from the indicated tissues 4 days after treatment and subjected to Western blot analysis as described in the Materials and methods. The data were quantified and expressed as means7s.e.m. of five separate measurements (lower panels). C, STZ-induced diabetic rats treated with control vector; Ins, STZ-induced diabetic rats treated with pEBAct-ins; Ins/G, STZ-induced diabetic rats treated with pEBAct-ins plus pEBAct-glut2. Statistically significant differences compared with C are indicated by *Po0.01.
Insulin gene therapy for diabetes YD Kim et al staining was not observed (Figure 1a) . Moreover, prolonged in vivo insulin gene expression was achieved by using the EBV replicon vector, as shown by the rat liver harvested 25 days after transfection (Figure 1d ). The liver cells normally expressed GLUT 2 ( Figure 1e ). Transfection with pEBAct-ins did not affect GLUT 2 expression levels, but transfection with pEBAct-glut2 markedly increased expression (Figure 1g ). These results were confirmed by Western blot analysis of GLUT 2 protein levels in primary isolated hepatocytes at 4 day after transfection (Figure 1h ).
Effect of cotransfecting insulin and GLUT 2 on blood glucose levels and body weight in STZ-induced diabetic rats STZ-induced diabetic rats showed extremely high fasting blood glucose levels that rose to 20.8270.39 mmol/l. In the rats treated with pEBAct-ins (with or without pEBAct-glut2), the fasting blood glucose levels dropped dramatically, close to the levels observed in nondiabetic rats (Figure 2a) . Normal blood glucose levels were maintained until 22 days after treament, until which point the glucose levels did not significantly differ from those of nondiabetic rats (Figure 2a ). The addition of pEBAct-glut2 to pEBAct-ins did not alter the fasting glucose levels.
While STZ treatment markedly reduced body weight, insulin-vector treatment induced a progressive gain in body weight. Notably, the addition of pEBAct-glut2 to the insulin treatment enhanced the rate of weight gain to the point statistically significant differences between the pEBAct-ins alone (Ins) and pEBAct-ins/-glut2 rats (Ins/G) started to be observed from day 20 to day 25 ( Figure 2b ).
Plasma insulin and C-peptide levels
To confirm that the hypoglycemic effects observed are due to hepatic insulin gene expression, we measured plasma insulin and C-peptide levels in 8 h-fasting rats treated or not with the insulin gene. At 4 days after treatment, negligible amounts of rat insulin and Cpeptide were found in the plasma of the STZ-induced diabetic rats, irrespective of whether or not they were treated with the insulin gene. In contrast, significant amounts of human insulin and C-peptide were detected in the plasma of diabetic Ins and Ins/G rats, indicating de novo synthesis from the delivered gene ( Figure 3 ). At day 25, plasma insulin levels decreased to B40% of the day 4 levels (Figure 3a) , which was also reflected by the increased blood glucose levels ( Figure 2a ).
Glucose responsiveness of the hypoglycemia induced by pEBAct-ins/-glut2 cotransfection
We examined whether cotransfecting pEBAct-ins and pEBAct-glut2 helps the diabetic rat to regulate its blood glucose levels in response to exogenous glucose loading. The intraperitoneal glucose tolerance test (IPGTT) revealed that the blood glucose levels of diabetic Ins/G rats peaked within 60 min and then decreased at 120 min, similar to the glucose levels of nondiabetic control rats. In diabetic Ins rats, fasting blood glucose levels were similar to those of control and diabetic Ins/G rats. However, the blood glucose levels at 120 min were significantly higher than those of nondiabetic control or diabetic Ins/G rats ( Figure 4a ). We also measured 2 h-postprandial glucose levels on day 4 and day 22. The rats were fasted for 12 h and then given dietary chow from 6 pm. Glucose levels measured at 8 pm showed that postprandial glucose levels in diabetic Ins/G rats were significantly lower than those in diabetic Ins rats ( Figure 4b ).
Stimulation of insulin secretion by glucose and glibenclamide
We asked whether the glucose-responsive hypoglycemia induced by pEBAct-ins/-glut2 cotransfection is mediated by glucose-stimulated insulin secretion. For this purpose, we transfected HepG2 human hepatoma cells with pEBAct-ins alone (HepG2ins) or with pEBAct-glut2 (HepG2ins/g). As shown in Figure 5a , the basal (5 mM glucose) insulin secretion of HepG2ins/g cells did not differ from that of HepG2ins cells. The static stimulation Figure 2 Effect of insulin and GLUT 2 vector transfection on fasting blood glucose levels and body weight. At 8-h-fasting blood glucose levels (a) and body weights (b) in STZ-induced diabetic rats (n ¼ 5 per group) were measured daily after injecting the indicated vector(s). NC, nondiabetic control rats; STZ-C, STZ-induced diabetic rats treated with control vector; Ins, STZ-induced diabetic rats treated with pEBAct-ins; Ins/G, STZ-induced diabetic rats treated with pEBAct-ins plus pEBACt-glut2; S, STZ injection day; T, day of treatment with pEBAct-ins with or without pEBAct-glut2. Values shown are means7s.e.m. Statistically significant differences compared with Ins/G are indicated by *Po0.05.
Insulin gene therapy for diabetes
YD Kim et al of HepG2ins/g with 25 mM glucose for 1 h significantly increased insulin secretion relative to the basal glucose level. In contrast, the static stimulation with 25 mM glucose did not increase the insulin secretion by HepG2ins cells. Thus, these data suggest that cotransfection of hepatic cells with pEBAct-ins/-glut2 elevates their glucose-responsive insulin secretion. We next examined the changes in plasma insulin levels in response to glibenclamdie. As shown in Figure 5b , plasma insulin levels of nondiabetic control rats gradually increased and peaked at 90 min after intraperitoneal glibenclamide administration. A similar trend was observed in diabetic Ins/G rats, even though the level of stimulation by glibenclamide was lower than in diabetic Ins/G rats. On the other hand, plasma insulin levels in diabetic Ins rats were not affected by glibenclamide. These data suggest that insulin secretion from hepatocytes in Ins/G rats was mediated by functional K ATP channels (see below).
Response of whole-cell membrane currents to high glucose stimulation
We next, investigated whether the in vivo and in vitro glucose-responsive insulin secretion induced by insulin and GLUT 2 vector cotransfection is mediated by functional K ATP channels. For this purpose, we measured the K ATP channel current in empty-vector-transfected HepG2, HepG2ins and HepG2ins/g cells by using the whole-cell patch-clamp technique ( Figure 6 ). The 200-ms ramp pulses from À100 to +80 mV were applied at a holding potential of À50 mV. To amplify the current through the K ATP channel, the channel-specific opener diazoxide (300 mM) was added to the bath solution prior to glucose application. The reversal potentials of the currents in the presence of diazoxide were around À40B to À50 mV in the three different cells, which suggests they are mainly K + currents. In addition, the recorded current was much greater in HepG2ins/g cells compared to that in the empty-vector-transfected HepG2 control and HepG2ins cells, implying that functional K ATP channel is more presented in the cell membrane of HepG2ins/g cells. When 20 mM glucose was added, the diazoxide-induced current was inhibited (Figure 6b ), suggesting that the K ATP channel responds to increase in ATP level by glucose in HepG2ins/g cells.
Liver toxicity analysis of HVJ-E vector containing EBV plasmid
As shown in Table 1 , elevations in liver function parameters were found in STZ-induced diabetic rats on day 4 and day 22, respectively. This was in contrast to STZ-induced diabetic rats, diabetic Ins and Ins/G rats, Postprandial glucose levels. Rats were fasted for 12 h before feeding and then 2-h-postprandial glucose levels were measured on day 4 and 22 after gene therapy. Horizontal bars mark the mean for each group (n ¼ 10). *Po0.001 and **Po0.01. NC, nondiabetic control rats; STZ-C, STZ-induced diabetic rats treated with control vector; Ins, STZ-induced diabetic rats treated with pEBAct-ins; Ins/G, STZinduced diabetic rat treated with pEBAct-ins plus pEBACt-glut2.
Insulin gene therapy for diabetes YD Kim et al which showed no relative changes in these parameters at day 4. Moreover, insulin gene transfer significantly improved these parameters on day 22 compared to STZinduced diabetic rats. A histological examination on day 22 of the liver tissue of diabetic Ins/G rats revealed no detectable damage, whereas liver tissue from STZinduced diabetic rat showed mild infiltration by inflammatory cells (data not shown).
Discussion
In the present study, we developed an alternative insulin gene transfection strategy that may be potentially more feasible in a clinical setting than existing strategies. This strategy involved direct liver injection of an HVJ-E vector bearing EBV replicon vectors encoding the insulin and GLUT 2 genes. Here, we report that application of this strategy to STZ-induced diabetic rats resulted in prolonged hepatic insulin gene expression and sustainted lowering of blood glucose levels. Moreover, we showed that when GLUT 2 was cotransfected with insulin, the blood glucose levels rose upon exogenous glucose loading and then returned to baseline with kinetics that resembled those in nondiabetic rats. In addition, postprandial glucose control in diabetic rats cotransfected with insulin and GLUT 2 was better than in diabetic rats transfected with insulin alone. We also showed that these effects are likely to be mediated by glucose-stimulated insulin secretion.
Pancreatic beta cells represent a highly differentiated cell type with specific properties, most notably, the regulated secretion of insulin. It is not easy to reconstruct this regulated system outside the pancreatic beta cells, as several cellular structures and proteins are required for the secretion of insulin in response to changes in extracellular glucose levels. In this regard, liver cells may turn out to be good candidates for regulated insulin secretion, as liver cells and pancreatic beta cells are similar in terms of their expression of GLUT 2 and the glucose phosphorylation enzyme glucokinase, which comprise the key elements of the glucose-sensing system. 27 Moreover, K ATP channels, which are the final effector molecules involved in insulin secretion in pancreatic beta cells, are normally expressed in liver cells. 28 However, K ATP channels in primary rat hepatocytes are not affected by voltage or Ca 2+ stimulation. 29 Thus, glucose-mediated ATP production and the subsequent reduced activity of functional K ATP channels are essential for the reconstruction of a glucose-responsive system. With regard to this, Liu et al. 9 reported that the coexpression of insulin and GLUT 2 genes in HepG2 cells inhibits functional K ATP channel currents and increases glucose-stimulated insulin secretion. We have confirmed these observations in this study. Moreover, when we employed these observations in the insulin gene therapy of STZ-induced diabetic rats, we found that diabetic Ins/ G rats had improved glucose tolerance and secreted more insulin in response to glibenclamide. As a result, postprandial glucose levels were more improved in diabetic Ins/G rats.
Unlike virus-based methods to deliver genes, nonviral delivery methods are considered to be safe, costeffective and less likely to induce immune responses. However, they are hampered by a more limited time span of transgene expression as well as lower gene transfer efficacy compared with viral vectors. 30 For example, it has been shown that while intravenous or intraportal treatment of STZ-induced diabetic rats with a nonviral vector expressing the insulin gene improved their blood glucose levels, the animals became hyperglycemic again within 1 week. 25, 31 The duration of gene expression can be improved by employing the EBVbased plasmid vector in various tissues, 10, 11, 32, 33 even though some reports showed prolonged gene expression without the EBV replicon. 34, 35 With regard to insulin gene delivery into liver, recently, Yasutomi et al. 33 reported that hydrodynamic-based transfection of diabetic mice liver with naked EBV-based plasmid vectors containing the proinsulin gene resulted in efficient hormone production. In this study, we found that the employment of EBV replicon vector system led to prolonged expression of the transfected insulin gene and lowering blood glucose levels did not significantly differ from those of nondiabetic rats for 22 days. On the other hand, transfection of 
Insulin gene therapy for diabetes
YD Kim et al
HVJ-E vector with insulin plasmids lacking EBV led to this range of fasting glucose levels only for 7 days (data not shown). It has been suggested that the EBV replicon vector may be more stable in nondividing rodent cells compared to dividing rodent cells, presumably because of its ability to be retained in the nucleus. Due to this, liver cells may be a good target for long-term expression of the insulin gene in the EBV replicon vector. The ability of the plasmid to autonomously replicate in human cell lines may be another advantage of the EBV replicon vector, 14, 32 which can be useful in clinical application. However, it will be necessary to develop a technique that enables more prolonged gene expression for this method to be used in a clinical context.
We and others have reported that HVJ-liposomemediated gene delivery is successful in transferring genes into target tissues. 12, [23] [24] [25] Our previous study showed that fasting blood glucose levels in STZ-induced diabetic rats were transiently normalized by portal vein injection of HVJ-liposomes containing human insulin expression vector. 31 Alternatively, repeated intravenous administrations of the insulin vector can also result in a sustained improvement of blood glucose levels in diabetic animals without antigenecity against HVJ. 25 However, systemic administration of the insulin gene may cause gene expression in an unwanted tissue and other systemic side effects. To overcome these issues, we developed a HVJ-E vector delivery system that is even more effective than HVJ-liposomes for in vivo gene transfer, especially when injected directly into the liver. 26 In this study, the target gene was delivered into a surgically exposed rat liver. However, ultrasound-guided In conclusion, liver-directed gene therapy using an HVJ-E vector containing EBV plasmids resulted in a prolonged decrease in blood glucose levels in STZinduced diabetic rats. Moreover, our data suggest that cotransfecting genes encoding insulin and the GLUT 2 transporter reconstitutes a physiologically regulated insulin secretion system in the diabetic rat liver. The present study provides a novel insulin gene therapy strategy that could be applied in clinical medicine in the future.
Materials and methods
Construction of plasmids
Furin-cleavable human preproinsulin cDNA was constructed as described previously. 18 Human GLUT 2 cDNA was purchased from Korea UniGene Information (Daejeon, Korea).
The EBV-based plasmid (pEBc) expression vector was constructed by subcloning the human insulin gene and the human GLUT 2 gene. The EBV-based plasmid contained the EBV origin of replication (oriP), the EBV nuclear antigen EBNA-1 and the ampicillin-resistance gene. pEBAct was constructed by replacing the cytomegalovirus promoter of pEBc with the chicken b-actin promoter derived from pAct-CAT. 36 pEBAct-ins was constructed by cloning the insulin gene into the BamHI/XbaI site of the pEBAct plasmid. pEBAct-glut2 was constructed by cloning the GLUT 2 gene into the EcoRI/NotI site of the pEBAct plasmid. The sequences of all the cloning plasmids were confirmed by DNA sequencing. Plasmids were amplified in DH-5a cells and purified by a Qiagen plasmid Maxi kit (Qiagen, Hilden, Germany).
Primary rat hepatocyte isolation and cell culture
Primary rat hepatocytes were isolated from rat liver at 4 days after transfection. Rats were anesthetized with sodium pentobarbital (50 mg/kg body weight) and the liver of each animal was surgically exposed. The liver was first perfused with resuspension buffer (150 mM NaCl, 10 mM KCl, 1 mM NaH 2 PO 4 Á 2H 2 O, 0.8 mM Na 2 HPO 4 Á 2H 2 O, 1 mM EGTA, 0.8 mM NaHCO 3 , 10 mM D-glucose, 10 mM HEPES, pH 7.2) at 30-50 ml/min for 5-10 min and was perfused with collagenase solution (HBSS (9.5 g/l), 0.8 mM NaHCO 3 , 0.9 mM CaCl 2 Á 2H 2 O, 10 mM HEPES, 0.5 g/l collagenase IA (Sigma, St Louis, MO, USA), 50 mg/l trypsin inhibitor, pH 7.5) at 30-50 ml/min for 5-10 min. After perfusion, the liver extract was chapped and filtered, and a pellet was obtained by centrifugation at 800 r.p.m. for 2-5 min at 41C. The hepatocyte viability greater than 80% as detected by trypan blue was used for protein extraction.
HepG2 human hepatoma cells were grown in DMEM (Gibco-BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA) penicillin (10 000 U/ml) and streptomycin (10 000 mg/ ml) at 371C in a 5% CO 2 humidified atmosphere.
Transfection of HepG2 cells and static stimulation of insulin secretion
HepG2 cells were maintained until reaching 60-80% confluence, after which 1 Â 10 5 cells/well were seeded in 12-well plates and fed with 1 ml/well culture medium prior to the transfection. All transfections were carried out with LipofectAmine 2000t reagent (Invitrogen, Carlsbad, CA, USA). The expression plasmid DNA and reagent (molar ratio; DNA:lipid ¼ 1:3) mixtures were added to the culture plates according to the manufacturer's instructions. After transfection, the cells were incubated at 371C for 5 h, after which culture medium with 0.5% FBS was added and the cells were cultured in a 5% CO 2 incubator for 24 h. To assess the effect of statically stimulating insulin secretion, the cells were incubated for 1 h in modified Krebs-Ringer bicarbonate buffer (114 mM NaCl, 4.4 mM KCl, 1 mM MgSO 4 , 29.5 mM NaHCO 3 , 1.28 mM CaCl 2 , 0.1% BSA, 10 mM HEPES, pH 7.4), after which 5 or 25 mM glucose was added for 1 h. The supernatant was collected and the secreted insulin levels were analyzed by using a rat insulin radioimmunoassay kit (Linco Research, St Charles, MO, USA).
Recordings of single K ATP channel activity
The whole-cell configuration of the conventional patchclamp technique was used to measure the diazoxideinduced K ATP current of HepG2ins, HepG2ins/g or empty-vector-transfected HepG2 cells. Patch pipettes had a resistance of 3-5 MO. The whole-cell currents were recorded by using an Axopatch 200B patch-clamp amplifier (Axon Instruments, Forster, CA, USA), passed onto an A/D converter (Digidata 1312; Axon) and later analyzed with Pclamp 8.2 software (Axon). Data were filtered at 5 kHz and sampled at 1 kHz.
During the experiments, single cells on a cover glass (10 Â 2 mm) were bathed in a solution composed of (in mM) 140 Na-acetate, 1 MgCl 2 , 1 CaCl 2 , 10 HEPES, adjusted to pH 7.4 with NaOH. The pipette solution contained (in mM) 136 K-acetate, 4 KCl, 1 EGTA, 10 HEPES, adjusted to pH 7.3 with KOH. The experiments were performed at room temperature (20-221C).
Diabetes induction by STZ
The 8-week-old male Sprague-Dawley rats (Hyochang, Daegu, Korea) weighing between 230 and 260 g were used. Diabetes was induced in rats by two consecutive intraperitoneal injections of STZ (80 mg/kg body weight; Sigma, St Louis, USA). Only rats with blood glucose levels above 300 mg/dl were kept in the protocol and randomized for the experiments. All procedures were in accordance with the institutional guidelines for animal research.
In vivo gene delivery
Diabetic rats were anesthetized with sodium pentobarbital (50 mg/kg body weight) and the liver of each animal was surgically exposed. The HVJ-E vector was donated by Ishihara Sangyo Kaisha Ltd (Osaka, Japan). The HVJ-E vector containing pEBAct-ins (100 mg) with or without pEBAct-glut2 (100 mg) was directly injected into four sites on the right lobe margin of the liver. After confirming the absence of backward flow, the rat abdomens were sutured.
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IPGTT and glibenclamide stimulation test
For IPGTT and glibeclamide stimulation tests, rats were fasted for 6 h, glucose (2 g/kg of body weight) or glibenclamide (10 mg/kg of body weight) was injected intraperitoneally, and blood was drawn from the tail vein every 15 or 30 min. Blood glucose and insulin levels were then measured.
Measurement of blood glucose, plasma insulin and C-peptide, and serum AST, ALT, ALP and total bilirubin levels
Blood glucose levels were measured by glucose reagent strips and a glucometer (Abbott) or by the glucose oxidase method (Cobas integra 800, Roche, Switzerland). Plasma insulin levels were measured by using an 125 Iinsulin double antibody rat insulin radioimmunoassay kit (Linco Research). This radioimmunoassay recognizes both proinsulin and active insulin of rat and human. C-peptide levels were measured by using a human or rat 125 I-C-peptide double antibody radioimmunoassay kit (Linco Research). The serum levels of AST, ALT, ALP and total bilirubin were measured in an autochemical analyzer (Hitachi 747, Tokyo, Japan) using the ultraviolet assay method.
Western blot analysis
The primary isolated hepatocytes were homogenized in IPH lysis buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 100 mM PMSF, 1 M DTT, 1 mg/ ml leupeptin, 1 mg/ml aprotinin). Cells were extracted at 41C for 30 min and then centrifuged at 12 000 r.p.m. for 20 min. The supernatant was collected and served as the cell lysate. Protein quantification was determined by using a Bradford protein assay system (Biorad Laboratories, Hercules, USA). Cell lysates (30 mg/lane) were subjected to 10% SDS-PAGE electrophoresis and transferred to an Immobilon-P-transfer-membrane (Millipore, Bedford, MA, USA). The membrane was reacted with rabbit anti-GLUT-2 1:1000 (Alpha Diagnostic, San Antonio, TX, USA), followed by incubation with a horseradish peroxidase-linked secondary antibody and detection using the ECL Western blotting detection system, as specified by the manufacturer.
Histological analysis
After their transfection with the HVJ-E vector, the animals were either killed when their glucose levels became lower (day 4) or at the end of the study (day 25). Liver tissues were collected by perfusion, fixed in 4% paraformaldehyde, and embedded in paraffin. For immunohistochemistry, 4 mm thick sections were cut, incubated with mouse anti-insulin monoclonal antibody (1:300 dilution; Chemicon, CA, USA) and processed for DakoCytomation (Dako Co, CA, USA) immunohistochemistry according to the standard manual protocol.
Statistical analysis
Results are expressed as mean7s.e.m. Analysis of variance was performed with Duncan's test and used to determine significant differences in multiple comparisons. Differences were considered to be statistically significant at Po0.05. All experiments were performed at least three times.
